$3.22
+0.13 (+4.04%)
Open$3.00
Previous Close$3.10
Day High$3.36
Day Low$2.90
52W High$15.15
52W Low$3.31
Volume—
Avg Volume28.6K
Market Cap4.68M
P/E Ratio—
EPS$-0.50
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+517.4% upside
Current
$3.22
$3.22
Target
$19.88
$19.88
$13.54
$19.88 avg
$24.91
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.5K | 10.4K | 653.1K |
| Net Income | -614,540 | -547,664 | 116.0K |
| Profit Margin | -5,863.7% | -5,570.5% | 17.8% |
| EBITDA | -627,942 | -590,696 | 172.6K |
| Free Cash Flow | — | — | 101.3K |
| Rev Growth | +1.0% | +1.0% | -9.1% |
| Debt/Equity | — | — | 0.30 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $250.82 | +0.83% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $417.84 | +0.40% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.14 | +1.67% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $516.44 | -1.77% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $805.97 | +1.00% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.12 | +1.42% | 35.2 | 28.41B |